This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $90.10 in the latest trading session, marking a -1.14% move from the prior day.
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Here's Why Momentum Investors Will Love Incyte (INCY)
by Zacks Equity Research
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Incyte
by Zacks Equity Research
Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Incyte (INCY) Is Up 1.88% in One Week: What You Should Know
by Zacks Equity Research
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
4 Big Biotech Stocks Worth Considering Post Q3 Earnings
by Zacks Equity Research
We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Will Incyte (INCY) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte
Earnings Season Clean Up: Global Week Ahead
by John Blank
71% of S&P 500 members have reported Q3 results. At Zacks, 'total earnings means 'aggregate net income' for those 357 S&P 500 members -- not mean, median or market-cap weighted EPS.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
Incyte (INCY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 26.15% and 2.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
Rising competition in international markets for Humira might have hurt AbbVie's (ABBV) top line in the third quarter. However, strong growth of Imbruvica is expected to have offset the loss.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
by Zacks Equity Research
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.